Logo
x

Search category

Subscribe Now

dermavant

Dermavant Reports P-III Study (ADORING 1) Results of Vtama (tapinarof) for Adults and Children with Atopic Dermatitis

Dermavant Reports P-III Study (ADORING 1) Results of Vtama (tapinarof) for Adults and Children with Atopic Dermatitis

  • May 16, 2023
Dermavant Reports P-III Trial (ADORING 2) Results of Vtama (tapinarof) for Atopic Dermatitis

Dermavant Reports P-III Trial (ADORING 2) Results of Vtama (tapinarof) for Atopic Dermatitis

  • March 16, 2023
Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

  • January 23, 2023
Philip Brown & Anna Tallman of Dermavant Shares Insights on the Approval of its Topical Treatment for Plaque Psoriasis

Philip Brown & Anna Tallman of Dermavant Shares Insights on the Approval of its Topical Treatment for Plaque Psoriasis

  • August 1, 2022
Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

Dermavant’s Vtama (tapinarof) Receives the US FDA’s Approval for the Treatment of Plaque Psoriasis in Adults

  • May 24, 2022
Dermavant Presents Results of Tapinarof Cream in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022

Dermavant Presents Results of Tapinarof Cream in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022

  • March 28, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.